These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
211 related articles for article (PubMed ID: 36594088)
1. Validation of ESM1 Related to Ovarian Cancer and the Biological Function and Prognostic Significance. Li YK; Zeng T; Guan Y; Liu J; Liao NC; Wang MJ; Chen KX; Luo XY; Chen CY; Quan FF; Wang J; Zhang QF; Zou J Int J Biol Sci; 2023; 19(1):258-280. PubMed ID: 36594088 [No Abstract] [Full Text] [Related]
2. ANGPTL4 accelerates ovarian serous cystadenocarcinoma carcinogenesis and angiogenesis in the tumor microenvironment by activating the JAK2/STAT3 pathway and interacting with ESM1. Li YK; Gao AB; Zeng T; Liu D; Zhang QF; Ran XM; Tang ZZ; Li Y; Liu J; Zhang T; Shi GQ; Zhou WC; Zou WD; Peng J; Zhang J; Li H; Zou J J Transl Med; 2024 Jan; 22(1):46. PubMed ID: 38212795 [TBL] [Abstract][Full Text] [Related]
3. Lactate drives the ESM1-SCD1 axis to inhibit the antitumor CD8 Fan Z; Ye M; Liu D; Zhou W; Zeng T; He S; Li Y Int Immunopharmacol; 2024 Aug; 137():112461. PubMed ID: 38897128 [TBL] [Abstract][Full Text] [Related]
4. Identification and validation of IRF6 related to ovarian cancer and biological function and prognostic value. Hong S; Fu N; Sang S; Ma X; Sun F; Zhang X J Ovarian Res; 2024 Mar; 17(1):64. PubMed ID: 38493179 [TBL] [Abstract][Full Text] [Related]
5. Pan-cancer analysis identifies ESM1 as a novel oncogene for esophageal cancer. Cui Y; Guo W; Li Y; Shi J; Ma S; Guan F Esophagus; 2021 Apr; 18(2):326-338. PubMed ID: 33175267 [TBL] [Abstract][Full Text] [Related]
6. ESM1 Is a Promising Therapeutic Target and Prognostic Indicator for Esophageal Carcinogenesis/Esophageal Squamous Cell Carcinoma. Li J; Yang D; Zhang C; Wei S; Zhao R; Dai S; Shan B Biomed Res Int; 2022; 2022():5328192. PubMed ID: 35937390 [TBL] [Abstract][Full Text] [Related]
7. PRR11 Overexpression Facilitates Ovarian Carcinoma Cell Proliferation, Migration, and Invasion Through Activation of the PI3K/AKT/β-Catenin Pathway. Zhu J; Hu H; Wang J; Yang Y; Yi P Cell Physiol Biochem; 2018; 49(2):696-705. PubMed ID: 30165366 [TBL] [Abstract][Full Text] [Related]
8. Identification of ESM1 as a Potential Biomarker Involving Drug Sensitivity and the Tumor Immune Microenvironment that Promotes Proliferation of Melanoma. Wang M; Ge H; Liang S; Chen G Cell Mol Biol (Noisy-le-grand); 2023 Jun; 69(6):160-167. PubMed ID: 37605575 [TBL] [Abstract][Full Text] [Related]
9. Endothelial cell-specific molecule 1 drives cervical cancer progression. Lu J; Liu Q; Zhu L; Liu Y; Zhu X; Peng S; Chen M; Li P Cell Death Dis; 2022 Dec; 13(12):1043. PubMed ID: 36522312 [TBL] [Abstract][Full Text] [Related]
10. ESM1 promotes triple-negative breast cancer cell proliferation through activating AKT/NF-κB/Cyclin D1 pathway. Liu W; Yang Y; He B; Ma F; Sun F; Guo M; Zhang M; Dong Z Ann Transl Med; 2021 Apr; 9(7):533. PubMed ID: 33987231 [TBL] [Abstract][Full Text] [Related]
11. ESM1 promotes angiogenesis in colorectal cancer by activating PI3K/Akt/mTOR pathway, thus accelerating tumor progression. Yang L; Dong Z; Li S; Chen T Aging (Albany NY); 2023 Mar; 15(8):2920-2936. PubMed ID: 37100467 [TBL] [Abstract][Full Text] [Related]
12. NUF2 promotes tumorigenesis by interacting with HNRNPA2B1 via PI3K/AKT/mTOR pathway in ovarian cancer. Ren M; Zhao H; Gao Y; Chen Q; Zhao X; Yue W J Ovarian Res; 2023 Jan; 16(1):17. PubMed ID: 36670423 [TBL] [Abstract][Full Text] [Related]
13. TEX19 promotes ovarian carcinoma progression and is a potential target for epitope vaccine immunotherapy. Xu Z; Tang H; Zhang T; Sun M; Han Q; Xu J; Wei M; Yu Z Life Sci; 2020 Jan; 241():117171. PubMed ID: 31843525 [TBL] [Abstract][Full Text] [Related]
14. Comprehensive bioinformatics analysis confirms RBMS3 as the central candidate biological target for ovarian cancer. Wang M; Fu X; Wang W; Zhang Y; Jiang Z; Gu Y; Chu M; Shao Y; Li S Med Eng Phys; 2022 Dec; 110():103883. PubMed ID: 36075788 [TBL] [Abstract][Full Text] [Related]
15. microRNA-1271-5p/TIAM1 suppresses the progression of ovarian cancer through inactivating Notch signaling pathway. Han FJ; Li J; Shen Y; Guo Y; Liu YC; Yu Y; Xu JY; Liu SX; Wang YH J Ovarian Res; 2020 Sep; 13(1):110. PubMed ID: 32948241 [TBL] [Abstract][Full Text] [Related]
16. SALL4 is a marker of poor prognosis in serous ovarian carcinoma promoting invasion and metastasis. Yang M; Xie X; Ding Y Oncol Rep; 2016 Mar; 35(3):1796-806. PubMed ID: 26750614 [TBL] [Abstract][Full Text] [Related]
17. F-Box and Leucine-Rich Repeat Protein 20 (FBXL20), Negatively Regulated by microRNA (miR)-195-5p, Accelerates the Malignant Progression of Ovarian Cancer. Wu D; Liu C; Hong L Mol Biotechnol; 2021 Dec; 63(12):1235-1243. PubMed ID: 34338995 [TBL] [Abstract][Full Text] [Related]
18. TEAD4 functions as a prognostic biomarker and triggers EMT via PI3K/AKT pathway in bladder cancer. Chi M; Liu J; Mei C; Shi Y; Liu N; Jiang X; Liu C; Xue N; Hong H; Xie J; Sun X; Yin B; Meng X; Wang B J Exp Clin Cancer Res; 2022 May; 41(1):175. PubMed ID: 35581606 [TBL] [Abstract][Full Text] [Related]
19. Targeting ESM1/ VEGFα signaling axis: a promising therapeutic avenue for angiogenesis in cervical squamous cell carcinoma. Li D; Su X; Xue S; Yao L; Yu D; Tang X; Huang Y J Cancer; 2023; 14(10):1725-1735. PubMed ID: 37476182 [No Abstract] [Full Text] [Related]
20. UBE2T is upregulated, predicts poor prognosis, and promotes cell proliferation and invasion by promoting epithelial-mesenchymal transition via inhibiting autophagy in an AKT/mTOR dependent manner in ovarian cancer. Huang W; Huang H; Xiao Y; Wang L; Zhang T; Fang X; Xia X Cell Cycle; 2022 Apr; 21(8):780-791. PubMed ID: 35130130 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]